ZYME just hosted their mid-year event where they updated investors on the status of ZW25 & ZW49.
Search Coverage List, Models & Reports
Search Results1-10 out of 254
The preprint for one of BNTX’s vaccine candidates came out this AM (07/01/20)… if you want to dig more into vaccines, see our COVID-19 Vaccine Bible.
We caught some interesting comments made by PFE’s CEO on their COVID-19 vaccine program that they’ve partnered with BNTX on... we expect ph1 data to be published very shortly.
BNTX just presented at the AACR its Ph.1 iNEST trial results in solid tumors, including data from both Ph.1a monotherapy (yesterday) and Ph1.b atezolizumab combo (this AM) studies.
PFE provided update on SB-525, its Gene therapy for HA this morning (06/18/20).
BMRN just updated their 4 yr Valrox data . Overall, the update was not surprising + looked in line with what we’ve put out in our preview note…here’s what you need to know:
Given the upcoming heme A readouts this week (BMRN’s valrox 4-yr update on Wednesday + PFE/SGMO’s SB-525 on Thursday) and next month (Roche’s SPK-5011), we wanted to set expectations for investors and provide some context re: the data we’re about to get.
MNTA just reported positive topline data from its Ph.2 MG trial that was being closely tracked by FcRn investors
Our vaccine deep dive conclusion: we’re cautiously optimistic on the vaccines front and believe there’s several approaches that could work given the biology of COVID-19 (we feel titers of 100 Nab = protective). Additionally, we feel the mRNA approaches can be immunogenic, and in turn avoid the ADE/th2 safety concerns.
- 1 of 26
- next →